

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. §371**

MERCK 2333

U.S. APPLICATION NO. (If known, see 37 CFR §1.5)

10/018484

INTERNATIONAL APPLICATION NO.

PCT/EP00/05278

INTERNATIONAL FILING DATE

7 JUNE 2000

PRIORITY DATE CLAIMED

19 JUNE 1999

TITLE OF INVENTION

THIENOPYRIMIDINES AS PHOSPHODIESTERASE INHIBITORS

APPLICANT(S) FOR DO/EO/US



JONAS, Rochus, et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. §371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. §371.
3. ☐ This express request to begin national examination procedures (35 U.S.C. §371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. §371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. §371(c)(2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ A translation of the International Application into English (35 U.S.C. §371(c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. §371(c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. §371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. §371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. §371(c)(5)).

Items 11. to 16. below concern document(s) or information included:


11. ☐ An Information Disclosure Statement under 37 C.F.R. §§1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. §§3.28 and 3.31 is included.
13. ☐ A FIRST preliminary amendment.
14. ☐ A SECOND or SUBSEQUENT preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☐ Other items or information:

U.S. APPLICATION NO. (if known) 10/018484 INTERNATIONAL APPLICATION NO. PCT/EP00/05278		ATTORNEY'S DOCKET NUMBER MERCK 2333	
17. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR §1.492 (a) (1) - (5)): Search Report has been prepared by the EPO or JPO..... \$890.00 International preliminary examination fee paid to USPTO (37 CFR §1.482)..... \$710.00 No international preliminary examination fee paid to USPTO (37 CFR §1.482) but international search fee paid to USPTO (37 CFR §1.445(a)(2))..... \$740.00 Neither international preliminary examination fee (37 CFR §1.482) nor international search fee (37 CFR §1.445(a)(2)) paid to USPTO..... \$1040.00 International preliminary examination fee paid to USPTO (37 CFR §1.482) and all claims satisfied provisions of PCT Article 33(2)-(4)..... \$100.00 ENTER APPROPRIATE BASIC FEE AMOUNT =		CALCULATIONS PTO USE ONLY \$890.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 C.F.R. §1.492(e)).			
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	9 - 20 =	0	x \$ 18.00
Independent claims	1 - 3 =	0	x \$ 84.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$ 280.00
TOTAL OF ABOVE CALCULATIONS =		\$890.00	
Reduction of 1/2 for filing by small entity, if applicable. A Verified Small Entity Statement must also be			
SUBTOTAL =		\$890.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 C.F.R. §1.492(f)).			
TOTAL NATIONAL FEE =		\$890.00	
Fee for recording the enclosed assignment (37 C.F.R. §1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 C.F.R. §§3.28, 3.31). \$40.00 per property.			
TOTAL FEES ENCLOSED =		\$890.00	
		Amount to be refunded:	
		charged:	
a. <input checked="" type="checkbox"/> A check in the amount of <u>\$890.00</u> to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. <u>13-3402</u> in the amount of \$_____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>13-3402</u> . A duplicate copy of this sheet is enclosed.			
NOTE: Where an appropriate time limit under 37 C.F.R. §§1.494 or 1.495 has not been met, a petition to revive (37 C.F.R. §1.137(a) or (b)) must be filed and granted to restore the application to pending status.			
SEND ALL CORRESPONDENCE TO: Customer Number 23,599			
 23599 PATENT TRADEMARK OFFICE		 SIGNATURE <u>Anthony J. Zelano</u> NAME <u>27,969</u> REGISTRATION NUMBER	
Filed: 18 DECEMBER 2001 AJZ:kmo			

Thienopyrimidines

The invention relates to compounds of the formula I

5



in which

10 R^1, R^2 in each case independently of one another are H, A, OH, OA or Hal,

X is R^4, R^5 or R^6 , which is monosubstituted by R^7 ,

15 R^4 is linear or branched alkylene having 1-10 C atoms, in which one or two CH_2 groups can be replaced by $-CH=CH-$ groups,

20 R^5 is cycloalkyl or cycloalkyl alkylene having 5-12 C atoms,

R^6 is phenyl or phenylmethyl,

25 R^7 is $COOH, COOA, CONH_2, CONHA, CON(A)_2$ or CN ,

A is alkyl having 1 to 6 C atoms and

Hal is F, Cl, Br or I,

30 where at least one of the radicals R^1 or R^2 is OH,

and their physiologically acceptable salts.

Pyrimidine derivatives have been disclosed, for example, in EP 201 188 or WO 93/06104.

The invention is based on the object of finding novel compounds having valuable properties, in particular those which can be used for the production of medicaments.

It has been found that the compounds of the formula I and their salts have very valuable pharmacological properties together with good tolerability.

In particular, they exhibit a specific inhibition of cGMP phosphodiesterase (PDE V).

Quinazolines having cGMP phosphodiesterase-inhibiting activity are described, for example, in J. Med. Chem. 36, 3765 (1993) and *ibid.* 37, 2106 (1994).

The biological activity of the compounds of the formula I can be determined by methods such as are described, for example, in WO 93/06104. The affinity of the compounds according to the invention for cGMP and cAMP phosphodiesterase is determined by the ascertainment of their IC₅₀ values (concentration of the inhibitor which is needed in order to achieve a 50% inhibition of the enzyme activity).

For carrying out the determinations, enzymes isolated according to known methods can be used (e.g. W.J. Thompson et al., Biochem. 1971, 10, 311). For carrying out the experiments, a modified "batch" method of W.J. Thompson and M.M. Appleman (Biochem. 1979, 18, 5228) can be used.

The compounds are therefore suitable for the treatment of disorders of the cardiovascular system, in particular cardiac insufficiency, and for the treatment and/or therapy of potency disorders (erectile dysfunction).

The use of substituted pyrazolopyrimidinones for the treatment of impotence is described, for example, in WO 94/28902.

The compounds are effective as inhibitors of the phenylephrine-induced contractions in corpus

cavernosum preparations of hares. This biological action can be demonstrated, for example, according to the method which is described by F. Holmquist et al. in J. Urol., 150, 1310-1315 (1993).

- 5 The inhibition of the contraction shows the efficacy of the compounds according to the invention for the therapy and/or treatment of potency disorders.


The compounds of the formula I can be employed as pharmaceutical active compounds in human and
10 veterinary medicine. In addition, they can be employed as intermediates for the preparation of further pharmaceutical active compounds.

The invention accordingly relates to the compounds of the formula I and to a process for the
15 preparation

of compounds of the formula I according to Claim 1 and their salts,

20 characterized in that

a) a compound of the formula II



II


25

in which

X has the meaning indicated,

30 and L is Cl, Br, OH, SCH₃ or a reactive esterified OH group,

is reacted with a compound of the formula III



in which

5 R^1 and R^2 have the meanings indicated,

or

10 b) in a compound of the formula I, a radical X is converted into another radical X by hydrolysing an ester group to a COOH group or converting a COOH group into an amide or into a cyano group

or

15 c) in a compound of the formula I, a radical R^1 and/or R^2 is converted into another radical R^1 and/or R^2 by converting an alkoxy group into a hydroxyl group,

20 and/or a compound of the formula I is converted into one of its salts.

Above and below, the radicals R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , X and L have the meanings indicated in the formulae I, II and III, if not expressly stated
25 otherwise.

A is alkyl having 1-6 C atoms.

In the above formulae, alkyl is preferably unbranched and has 1, 2, 3, 4, 5 or 6 C atoms and is preferably methyl, ethyl or propyl, furthermore preferably
30 isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, but also n-pentyl, neopentyl, isopentyl or hexyl.

X is an R^4 , R^5 or R^6 radical which is monosubstituted by R^7 .

R^4 is a linear or branched alkylene radical
35 having 1-10 C atoms, where the alkylene radical is preferably, for example, methylene, ethylene,

propylene, isopropylene, butylene, isobutylene, sec-butylene, pentylene, 1-, 2- or 3-methylbutylene, 1,1-, 1,2- or 2,2-dimethylpropylene, 1-ethylpropylene, hexylene, 1-, 2-, 3- or 4-methylpentylene, 1,1-, 1,2-, 1,3-, 2,2-, 2,3- or 3,3-dimethylbutylene, 1- or 2-ethylbutylene, 1-ethyl-1-methylpropylene, 1-ethyl-2-methylpropylene, 1,1,2- or 1,2,2-trimethylpropylene, linear or branched heptylene, octylene, nonylene or decylene.

10 R^4 is furthermore, for example, but-2-enylene or hex-3-enylene.

Ethylene, propylene or butylene is very particularly preferred.

15 R^5 is cycloalkylalkylene having 5-12 C atoms, preferably, for example, cyclopentylmethylene, cyclohexylmethylene, cyclohexylethylene, cyclohexylpropylene or cyclohexylbutylene.

R^5 is also cycloalkyl preferably having 5-7 C atoms. Cycloalkyl is, for example, cyclopentyl, cyclohexyl or 20 cycloheptyl.

Hal is preferably F, Cl or Br, but also I.

The radicals R^1 and R^2 can be identical or different and are preferably in the 3- or 4-position of the phenyl ring. They are, for example, in each case 25 independently of one another H, alkyl, alkoxy, hydroxyl, F, Cl, Br or I. Preferably, they are independently of one another Hal and hydroxyl. At least one of the radicals R^1 and R^2 is hydroxyl.

The radical R^7 is preferably, for example, 30 COOH , COOCH_3 , COOC_2H_5 , CONH_2 , $\text{CON}(\text{CH}_3)_2$, CONHCH_3 or CN .

It applies to the whole invention that all radicals which occur a number of times can be identical or different, i.e. are independent of one another.

Accordingly, the invention relates, in 35 particular to those compounds of the formula I in which at least one of the radicals mentioned has one of the preferred meanings indicated above.

Some preferred groups of compounds can be expressed by the following subformulae Ia to Id, which

correspond to the formula I and in which the radicals not designated in greater detail have the meaning indicated in the formula I, but in which

- 5 in Ia X is R⁴, phenyl or phenylmethyl, which is substituted by COOH, COOA, CONH₂, CONA₂, CONHA or CN;
- 10 in Ib R¹, R² in each case independently of one another are H, A, OH, OA or Hal,
X is R⁴, phenyl or phenylmethyl, which is substituted by COOH, COOA, CONH₂, CONA₂, CONHA or CN;
where at least one of the radicals R¹ and R² is
15 OH;
- in Ic R¹, R² in each case independently of one another are H, A, OA or Hal,
20 X is alkylene having 2-5 C atoms, cyclohexyl, phenyl or phenylmethyl, which is monosubstituted by R⁷,
R⁷ is COOH or COOA,
A is alkyl having 1-6 C atoms,
Hal is F, Cl, Br or I,
25 where at least one of the radicals R¹ and R² is OH;
- in Id R¹ is Hal,
R² is OH,
30 X is alkylene having 2-5 C atoms, cyclohexyl, phenyl or phenylmethyl, which is monosubstituted by R⁷,
R⁷ is COOH or COOA,
A is alkyl having 1-6 C atoms,
35 Hal is F, Cl, Br or I,

and their physiologically acceptable salts.

The compounds of the formula I and also the starting substances for their preparation are otherwise

prepared by methods known per se, such as are described in the literature (e.g. in the standard works such as Houben-Weyl, Methoden der organischen Chemie [Methods of Organic Chemistry], Georg-Thieme-Verlag, Stuttgart),
5 namely under reaction conditions which are known and suitable for the reactions mentioned. Use can also be made in this case of variants which are known per se, but not mentioned here in greater detail.

In the compounds of the formula II or III, R^1 ,
10 R^2 , R^3 , R^4 , X and n have the meanings indicated, in particular the preferred meanings indicated.

If L is a reactive esterified OH group, this is preferably alkylsulfonyloxy having 1-6 C atoms (preferably methylsulfonyloxy) or arylsulfonyloxy
15 having 6-10 C atoms (preferably phenyl- or p-tolylsulfonyloxy, in addition also 2-naphthalenesulfonyloxy).

The compounds of the formula I can preferably be obtained by reacting compounds of the formula II
20 with compounds of the formula III.

If desired, the starting substances can also be formed in situ, such that they are not isolated from the reaction mixture, but immediately reacted further to give the compounds of the formula I.

25 On the other hand, it is possible to carry out the reaction stepwise.

As a rule, the starting compounds of the formulae II and III are known. If they are not known, they can be prepared by methods known per se.

30 Compounds of the formula II can be obtained, e.g. by reaction with $POCl_3$, from the corresponding hydroxypyrimidines, which are synthesized from thiophene derivatives and CN-substituted alkylene carboxylic acid esters. (Eur. J. Med. Chem. 23, 453
35 (1988)).

The hydroxypyrimidines are prepared either by dehydrogenation of corresponding tetrahydrobenzothienopyrimidine compounds or by the cyclization of 2-aminobenzothiophene-3-carboxylic acid derivatives with

aldehydes or nitriles, which is customary for the preparation of pyrimidine derivatives (e.g. Houben Weyl E9b/2).

Specifically, the reaction of the compounds of the formula II with the compounds of the formula III is carried out in the presence or the absence of an inert solvent at temperatures between approximately -20 and approximately 150°, preferably between 20 and 100°.

The addition of an acid-binding agent, for example of an alkali metal or alkaline earth metal hydroxide, carbonate or bicarbonate or of another salt of a weak acid of the alkali metals or alkaline earth metals, preferably of potassium, sodium or calcium, or the addition of an organic base such as triethylamine, dimethylamine, pyridine or quinoline, or an excess of the amine components can be favourable.

Suitable inert solvents are, for example, hydrocarbons such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons such as trichloroethylene, 1,2-dichloroethane, carbontetrachloride, chloroform or dichloromethane; alcohols such as methanol, ethanol, isopropanol, n-propanol, n-butanol or tert-butanol; ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; glycol ethers such as ethylene glycol monomethyl or monoethyl ether (methyl glycol or ethyl glycol), ethylene glycol dimethyl ether (diglyme); ketones such as acetone or butanone; amides such as acetamide, dimethylacetamide, N-methylpyrrolidone or dimethylformamide (DMF); nitriles such as acetonitrile; sulfoxides such as dimethyl sulfoxide (DMSO); nitro compounds such as nitromethane or nitrobenzene; esters such as ethyl acetate or mixtures of the solvents mentioned.

It is furthermore possible to convert a radical X in a compound of the formula I into another radical X, e.g. by hydrolysing an ester or a cyano group to a COOH group.

Ester groups can be hydrolysed, for example, using NaOH or KOH in water, water-THF or water-dioxane at temperatures between 0 and 100°.

Carboxylic acids can be converted, for example
5 using thionyl chloride, into the corresponding carboxylic acid chlorides and these can be converted into carboxamides. By elimination of water in a known manner, carbonitriles are obtained from these.

Compounds of the formula I in which R¹ and/or R² are OA
10 can be converted according to known methods of ether cleavage into the corresponding compounds of the formula I in which R¹ and/or R² is hydroxyl.

An acid of the formula I can be converted into the associated acid addition salt using a base, for
15 example by reaction of equivalent amounts of the acid and of the base in an inert solvent such as ethanol and subsequent evaporation. Suitable bases for this reaction are in particular those which yield physiologically acceptable salts.

20 Thus the acid of the formula I can be converted into the corresponding metal salt, in particular alkali metal or alkaline earth metal salt, or into the corresponding ammonium salt using a base (e.g. sodium or potassium hydroxide or carbonate).

25 For this reaction, suitable organic bases are in particular also those which yield physiologically acceptable salts, such as, for example, ethanolamine.

On the other hand, a base of the formula I can be converted into the associated acid addition salt
30 using an acid, for example by reaction of equivalent amounts of the base and of the acid in an inert solvent such as ethanol and subsequent evaporation. For this reaction, suitable acids are in particular those which yield physiologically acceptable salts. Thus inorganic
35 acids can be used, e.g. sulfuric acid, nitric acid, hydrohalic acids such as hydrochloric acid or hydrobromic acid, phosphoric acids such as orthophosphoric acid, sulfamic acid, furthermore organic acids, in particular aliphatic, alicyclic,

araliphatic, aromatic or heterocyclic mono- or polybasic carboxylic, sulfonic or sulfuric acids, e.g. formic acid, acetic acid, propionic acid, pivalic acid, diethylacetic acid, malonic acid, succinic acid, 5 pimelic acid, fumaric acid, maleic acid, lactic acid, tartaric acid, malic acid, citric acid, gluconic acid, ascorbic acid, nicotinic acid, isonicotinic acid, methane- or ethanesulfonic acid, ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 10 p-toluenesulfonic acid, naphthalenemono- and disulfonic acids, and laurylsulfuric acid. Salts with physiologically unacceptable acids, e.g. picrates, can be used for the isolation and/or purification of the compounds of the formula I.

15 The invention furthermore relates to the use of the compounds of the formula I and/or their physiologically acceptable salts for the production of pharmaceutical preparations, in particular by a non-chemical route. In this connection, they can be brought 20 into a suitable dose form together with at least one solid, liquid and/or semi-liquid vehicle or excipient and, if appropriate, in combination with one or more further active compounds.

The invention also relates to medicaments of 25 the formula I and their physiologically acceptable salts as phosphodiesterase V inhibitors.

The invention further relates to pharmaceutical preparations, comprising at least one compound of the formula I and/or one of its physiologically acceptable 30 salts.

These preparations can be used as medicaments in human or veterinary medicine. Suitable vehicles are organic or inorganic substances which are suitable for enteral (e.g. oral) or parenteral administration or 35 topical application and do not react with the novel compounds, for example water, vegetable oils, benzyl alcohols, alkylene glycols, polyethylene glycols, glyceryl triacetate, gelatine, carbohydrates such as lactose or starch, magnesium stearate, talc and

petroleum jelly. In particular, tablets, pills, coated tablets, capsules, powders, granules, syrups, juices or drops are used for oral administration, suppositories are used for rectal administration, solutions, preferably oily or aqueous solutions, furthermore suspensions, emulsions or implants, are used for parenteral administration, and ointments, creams or powders are used for topical application. The novel compounds can also be lyophilized and the lyophilizates obtained used, for example, for the production of injection preparations. The preparations indicated can be sterilized and/or can contain excipients such as lubricants, preservatives, stabilizers and/or wetting agents, emulsifiers, salts for influencing the osmotic pressure, buffer substances, colourants, flavourings and/or one or more further active compounds, e.g. one or more vitamins.

The compounds of the formula I and their physiologically acceptable salts can be employed in the control of diseases in which an increase in the cGMP (cyclic guanosin monophosphate) level leads to inhibition or prevention of inflammation and muscle relaxation. The compounds according to the invention can particularly be used in the treatment of diseases of the cardiovascular system and for the treatment and/or therapy of potency disorders.

In this connection, the substances are as a rule preferably administered in doses of between approximately 1 and 500 mg, in particular between 5 and 100 mg, per dose unit. The daily dose is preferably between approximately 0.02 and 10 mg/kg of body weight. The specific dose for each patient depends, however, on all sorts of factors, for example on the efficacy of the specific compound employed, on the age, body weight, general state of health, sex, on the diet, on the time and route of administration, and on the excretion rate, pharmaceutical combination and severity of the particular disorder to which the therapy applies. Oral administration is preferred.

Above and below, all temperatures are indicated in °C. In the following examples, "customary working-up" means: if necessary, water is added, the pH is adjusted, if necessary, depending on the constitution of the final product, to a value of between 2 and 10, the mixture is extracted with ethyl acetate or dichloromethane, the organic phase is separated off, dried over sodium sulfate and evaporated, and the residue is purified by chromatography on silica gel and/or by crystallization.

Mass spectrometry (MS): EI (electron impact ionization) M^+

FAB (fast atom bombardment) $(M+H)^+$

15 Example 1

Methyl 3-(4-chlorobenzothieno[2,3-d]pyrimidin-2-yl)propionate [obtainable by cyclization of methyl 2-amino-5,6,7,8-tetrahydrobenzothiophene-3-carboxylate with methyl 3-cyanopropionate, dehydrogenation with sulfur and subsequent chlorination with phosphorus oxychloride/dimethylamine] and 3-chloro-4-methoxybenzylamine ("A") in N-methylpyrrolidone are stirred at 110° for 5 hours. The solvent is removed and the residue is worked up in the customary manner. Methyl 3-[4-(3-chloro-4-methoxybenzylamino)benzothieno[2,3-d]pyrimidin-2-yl]propionate is obtained as a colourless oil.

The following is obtained analogously by reaction of "A"

with methyl 2-(4-chlorobenzothieno[2,3-d]pyrimidin-2-yl)acetate

methyl 2-[4-(3-chloro-4-methoxybenzylamino)benzothieno[2,3-d]pyrimidin-2-yl]acetate.

The following is obtained analogously by reaction of "A"

with methyl 4-(4-chlorobenzothieno[2,3-d]pyrimidin-2-yl)butyrate

methyl 4-[4-(3-chloro-4-methoxybenzylamino)benzothieno[2,3-d]pyrimidin-2-yl]butyrate.

5

The following is obtained analogously by reaction of "A"

with methyl 5-(4-chlorobenzothieno[2,3-d]pyrimidin-2-yl)valerate

10

methyl 5-[4-(3-chloro-4-methoxybenzylamino)benzothieno[2,3-d]pyrimidin-2-yl]valerate.

The following is obtained analogously by reaction of "A"

15

with methyl 7-(4-chlorobenzothieno[2,3-d]pyrimidin-2-yl)heptanoate

20

methyl 7-[4-(3-chloro-4-methoxybenzylamino)benzothieno[2,3-d]pyrimidin-2-yl]heptanoate.

The following is obtained analogously by reaction of "A"

with methyl 2-[4-(4-chlorobenzothieno[2,3-d]pyrimidin-2-yl)cyclohex-1-yl]acetate

25

methyl 2-{4-[4-(3-chloro-4-methoxybenzylamino)benzothieno[2,3-d]pyrimidin-2-yl]cyclohex-1-yl}acetate

The following is obtained analogously by reaction of "A"

30

with methyl 4-(4-chlorobenzothieno[2,3-d]pyrimidin-2-yl)cyclohexanecarboxylate

35

methyl 4-[4-(3-chloro-4-methoxybenzylamino)benzothieno[2,3-d]pyrimidin-2-yl]cyclohexanecarboxylate.

Example 2

Methyl 3-[4-(3-chloro-4-methoxybenzylamino)benzothieno-
[2,3-d]pyrimidin-2-yl]propionate is dissolved in
5 ethylene glycol monomethyl ether and stirred at 110°
for 5 hours after addition of 32% NaOH. After addition
of 20% HCl, the mixture is extracted with
dichloromethane. By addition of petroleum ether,
3-[4-(3-chloro-4-methoxybenzylamino)benzothieno[2,3-d]-
10 pyrimidin-2-yl]propionic acid, m.p. 218°, is obtained.

The precipitated crystals are dissolved in
isopropanol and treated with ethanolamine. After
crystallization, 3-[4-(3-chloro-4-methoxybenzylamino)-
benzothieno[2,3-d]pyrimidin-2-yl]propionic acid,
15 ethanolamine salt, is obtained.

The compounds

4-[4-(3-chloro-4-methoxybenzylamino)benzothieno-
[2,3-d]pyrimidin-2-yl]butyric acid, m.p. 225°;
ethanolamine salt m.p. 150°;

20 5-[4-(3-chloro-4-methoxybenzylamino)benzothieno-
[2,3-d]pyrimidin-2-yl]valeric acid, m.p. 210°;
ethanolamine salt m.p. 141°

25 are obtained analogously.

The carboxylic acids below are obtained
analogously from the esters listed under Example 1:

30 2-[4-(3-chloro-4-methoxybenzylamino)benzothieno-
[2,3-d]pyrimidin-2-yl]acetic acid,

7-[4-(3-chloro-4-methoxybenzylamino)benzothieno-
[2,3-d]pyrimidin-2-yl]heptanoic acid,

35 2-{4-[4-(3-chloro-4-methoxybenzylamino)benzo-
thieno[2,3-d]pyrimidin-2-yl]cyclohex-1-yl}acetic acid,

4-[4-(3-chloro-4-methoxybenzylamino)benzothieno-
[2,3-d]pyrimidin-2-yl]cyclohexanecarboxylic acid,
ethanolamine salt, m.p. 167°.

5 Example 3

A mixture of 1.5 g of methyl 4-(4-chlorobenzothieno[2,3-d]pyrimidin-2-yl)phenylcarboxylate ("B"), prepared by dehydrogenation
10 of the corresponding 5,6,7,8-tetrahydrobenzothieno[2,3-d]pyrimidine compound with sulfur and subsequent chlorination with phosphorus oxychloride/dimethylamine, and 1.5 g of 3-chloro-4-methoxybenzylamine in 20 ml of N-methylpyrrolidone is heated at 110° for 4 hours.
15 After cooling, the mixture is worked up in the customary manner. 2.6 g of methyl 4-[4-(3-chloro-4-methoxybenzylamino)benzothieno[2,3-d]pyrimidin-2-yl]-benzoate, m.p. 203-204°, are obtained.

Analogously to Example 2, 1.0 g of
20 4-[4-(3-chloro-4-methoxybenzylamino)benzothieno-
[2,3-d]pyrimidin-2-yl]benzoic acid, ethanolamine salt, m.p. 189-190°, are obtained from 1.2 g of the ester thereof.

The compound 4-[4-(3-chloro-4-methoxybenzyl-
25 amino)benzothieno[2,3-d]pyrimidin-2-yl]phenylacetic
acid, ethanolamine salt, m.p. 130°, is obtained analogously.

Example 4

30 1 equivalent of 3-[4-(3-chloro-4-methoxybenzyl-
amino)benzothieno[2,3-d]pyrimidin-2-yl]propionic acid
and 1.2 equivalents of thionyl chloride are stirred in
dichloromethane for 2 hours. The solvent is removed and
35 3-[4-(3-chloro-4-methoxybenzylamino)benzothieno[2,3-d]-
pyrimidin-2-yl]propionyl chloride is obtained.
The mixture is transferred to aqueous ammonia, stirred
for one hour and, after customary working up, 3-[4-(3-

chloro-4-methoxybenzylamino)benzothieno[2,3-d]pyrimidin-2-yl]propionamide is obtained.

Example 5

5

1 equivalent of DMF and 1 equivalent of oxalyl chloride are dissolved in acetonitrile at 0°. 1 equivalent of 3-[4-(3-chloro-4-methoxybenzylamino)-benzothieno[2,3-d]pyrimidin-2-yl]propionamide is then added. The mixture is subsequently stirred for one hour. After customary working up, 3-[4-(3-chloro-4-methoxybenzylamino)benzothieno[2,3-d]pyrimidin-2-yl]-propionitrile is obtained.

15

Example 6

The compounds obtained in Examples 1 to 5 can be converted into the corresponding hydroxyl compounds by known methods of ether cleavage. The compounds below

20

methyl 3-[4-(3-chloro-4-hydroxybenzylamino)benzothieno[2,3-d]pyrimidin-2-yl]propionate,

25

methyl 2-[4-(3-chloro-4-hydroxybenzylamino)benzothieno[2,3-d]pyrimidin-2-yl]acetate,

30

methyl 5-[4-(3-chloro-4-hydroxybenzylamino)benzothieno[2,3-d]pyrimidin-2-yl]valerate,

35

methyl 7-[4-(3-chloro-4-hydroxybenzylamino)benzothieno[2,3-d]pyrimidin-2-yl]heptanoate,

methyl 2-{4-[4-(3-chloro-4-hydroxybenzylamino)-benzothieno[2,3-d]pyrimidin-2-yl]cyclohex-1-yl}acetate,

methy 4-[4-(3-chloro-4-hydroxybenzylamino)benzothieno[2,3-d]pyrimidin-2-yl]cyclohexanecarboxylate,

3-[4-(3-chloro-4-hydroxybenzylamino)benzothieno-
5 [2,3-d]pyrimidin-2-yl]propionic acid,

4-[4-(3-chloro-4-hydroxybenzylamino)benzothieno-
[2,3-d]pyrimidin-2-yl]butyric acid,

10 5-[4-(3-chloro-4-hydroxybenzylamino)benzothieno-
[2,3-d]pyrimidin-2-yl]valeric acid,

2-[4-(3-chloro-4-hydroxybenzylamino)benzothieno-
[2,3-d]pyrimidin-2-yl]acetic acid,
15

7-[4-(3-chloro-4-hydroxybenzylamino)benzothieno-
[2,3-d]pyrimidin-2-yl]heptanoic acid,

2-[4-[4-(3-chloro-4-hydroxybenzylamino)benzothieno[2,3-d]pyrimidin-2-yl]cyclohex-1-yl]acetic acid,
20

4-[4-(3-chloro-4-hydroxybenzylamino)benzothieno-
[2,3-d]pyrimidin-2-yl]cyclohexanecarboxylic acid,

25 4-[4-(3-chloro-4-hydroxybenzylamino)benzothieno-
[2,3-d]pyrimidin-2-yl]benzoic acid,

4-[4-(3-chloro-4-hydroxybenzylamino)benzothieno-
[2,3-d]pyrimidin-2-yl]phenylacetic acid,
30

3-[4-(3-chloro-4-hydroxybenzylamino)benzothieno-
[2,3-d]pyrimidin-2-yl]propionamide,

3-[4-(3-chloro-4-hydroxybenzylamino)benzothieno-
35 [2,3-d]pyrimidin-2-yl]propionitrile,

are thus obtained.

Example 7

Analogously to Example 1, by reaction of
0.01 mol of methyl 4-(4-chlorobenzothieno[2,3-
5 d]pyrimidin-2-yl)cyclohexanecarboxylate with 0.02 mol
of 3-chloro-4-hydroxybenzylamine in 40 ml of 1-methyl-
2-pyrrolidone, after customary working up

methyl 4-[4-(3-chloro-4-hydroxybenzylamino)benzo-
10 thieno[2,3-d]pyrimidin-2-yl]cyclohexanecarboxylate

is obtained.

The compounds
15

methyl 4-[4-(3-methoxy-4-hydroxybenzylamino)benzo-
thieno[2,3-d]pyrimidin-2-yl]cyclohexanecarboxylate and

methyl 4-[4-(4-hydroxybenzylamino)benzothieno-
20 [2,3-d]pyrimidin-2-yl]cyclohexanecarboxylate

are obtained analogously.

By ester hydrolysis analogously to Example 2,
25 the compounds

4-[4-(3-chloro-4-hydroxybenzylamino)benzothieno-
[2,3-d]pyrimidin-2-yl]cyclohexanecarboxylic acid,
ethanolamine salt, m.p. 200-202°;
30

4-[4-(3-methoxy-4-hydroxybenzylamino)benzothieno-
[2,3-d]pyrimidin-2-yl]cyclohexanecarboxylic acid,

4-[4-(4-hydroxybenzylamino)benzothieno[2,3-d]-
35 pyrimidin-2-yl]cyclohexanecarboxylic acid

are obtained therefrom.

The compounds below

4-[4-(3-methoxy-4-hydroxybenzylamino)benzothieno-
[2,3-d]pyrimidin-2-yl]butyric acid,

5 5-[4-(3-methoxy-4-hydroxybenzylamino)benzothieno-
[2,3-d]pyrimidin-2-yl]valeric acid,

2-[4-(3-methoxy-4-hydroxybenzylamino)benzothieno-
[2,3-d]pyrimidin-2-yl]acetic acid,

10

7-[4-(3-methoxy-4-hydroxybenzylamino)benzothieno-
[2,3-d]pyrimidin-2-yl]heptanoic acid,

15

2-{4-[4-(3-methoxy-4-hydroxybenzylamino)benzo-
thieno[2,3-d]pyrimidin-2-yl]cyclohex-1-yl}acetic acid,

4-[4-(4-hydroxybenzylamino)benzothieno[2,3-d]-
pyrimidin-2-yl]butyric acid,

20

5-[4-(4-hydroxybenzylamino)benzothieno[2,3-d]-
pyrimidin-2-yl]valeric acid,

2-[4-(4-hydroxybenzylamino)benzothieno[2,3-d]-
pyrimidin-2-yl]acetic acid,

25

7-[4-(4-hydroxybenzylamino)benzothieno[2,3-d]-
pyrimidin-2-yl]heptanoic acid,

30

2-{4-[4-(4-hydroxybenzylamino)benzothieno[2,3-d]-
pyrimidin-2-yl]cyclohex-1-yl}acetic acid,

3-{4-[4-(4-hydroxybenzylamino)benzothieno[2,3-d]-
pyrimidin-2-yl]cyclohex-1-yl}propionic acid

35 are obtained analogously.

The following examples relate to pharmaceutical preparations:

Example A: Injection vials

5

A solution of 100 g of an active compound of the formula I and 5 g of disodium hydrogenphosphate is adjusted to pH 6.5 in 3 l of double-distilled water using 2 N hydrochloric acid, sterile filtered, dispensed into injection vials, lyophilized under sterile conditions and aseptically sealed. Each injection vial contains 5 mg of active compound.

Example B: Suppositories

15

A mixture of 20 g of an active compound of the formula I is fused with 100 g of soya lecithin and 1400 g of cocoa butter, poured into moulds and allowed to cool. Each suppository contains 20 mg of active compound.

Example C: Solution

A solution is prepared from 1 g of an active compound of the formula I, 9.38 g of $\text{NaH}_2\text{PO}_4 \cdot 2\text{H}_2\text{O}$, 28.48 g of $\text{Na}_2\text{HPO}_4 \cdot 12\text{H}_2\text{O}$ and 0.1 g of benzalkonium chloride in 940 ml of double-distilled water. The solution is adjusted to pH 6.8, made up to 1 l and sterilized by irradiation. This solution can be used in the form of eye drops.

Example D: Ointment

500 mg of an active compound of the formula I are mixed with 99.5 g of petroleum jelly under aseptic conditions.

Example E: Tablets

A mixture of 1 kg of active compound of the formula I, 4 kg of lactose, 1.2 kg of potato starch, 0.2 kg of talc and 0.1 kg of magnesium stearate is compressed in a customary manner to give tablets such that each tablet contains 10 mg of active compound.

Example F: Coated tablets

Analogously to Example E, tablets are pressed and are then coated in a customary manner with a coating of sucrose, potato starch, talc, tragacanth and colourant.

Example G: Capsules

2 kg of active compound of the formula I are filled into hard gelatine capsules in a customary manner such that each capsule contains 20 mg of the active compound.

Example H: Ampoules


A solution of 1 kg of active compound of the formula I in 60 l of double-distilled water is sterile filtered, dispensed into ampoules, lyophilized under sterile conditions and aseptically sealed. Each ampoule contains 10 mg of active compound.

Example I: Inhalation spray

14 g of active compound of the formula I is dissolved in 10 l of isotonic NaCl solution and the solution is filled into commercially available spray containers having a pump mechanism. The solution can be sprayed into the mouth or nose. One burst of spray (approximately 0.1 ml) corresponds to a dose of approximately 0.14 mg.

22
Patent Claims

1. Compounds of the formula I



in which

R^1 , R^2 in each case independently of one another are
H, A, OH, OA or Hal,

X is R^4 , R^5 or R^6 , which is monosubstituted by R^7 ,

R^4 is linear or branched alkylene having 1-10 C atoms, in which one or two CH_2 groups can be replaced by $-CH=CH-$ groups,

R^5 is cycloalkyl or cycloalkyl alkylene having 5-12 C atoms,

R^6 is phenyl or phenylmethyl,

R^7 is $COOH$, $COOA$, $CONH_2$, $CONHA$, $CON(A)_2$ or CN ,

A is alkyl having 1 to 6 C atoms and

Hal is F, Cl, Br or I,

where at least one of the radicals R^1 or R^2 is OH,

and their physiologically acceptable salts.

2. Compounds of the formula I according to Claim 1

(a) 3-[4-(3-chloro-4-hydroxybenzylamino)benzo[4,5]-thieno[2,3-d]pyrimidin-2-yl]propionic acid;

5 (b) 7-[4-(3-chloro-4-hydroxybenzylamino)benzo[4,5]-thieno[2,3-d]pyrimidin-2-yl]heptanoic acid;

(c) 5-[4-(3-chloro-4-hydroxybenzylamino)benzo[4,5]-thieno[2,3-d]pyrimidin-2-yl]valeric acid;

10 (d) 2-{4-[4-(3-chloro-4-hydroxybenzylamino)benzo[4,5]-thieno[2,3-d]pyrimidin-2-yl]cyclohex-1-yl}acetic acid;


(e) 4-[4-(3-chloro-4-hydroxybenzylamino)benzothieno-
15 [2,3-d]pyrimidin-2-yl]cyclohexanecarboxylic acid

and their physiologically acceptable salts.

3. Process for the preparation of compounds of the
20 formula I according to Claim 1 and their salts,

characterized in that

a) a compound of the formula II
25




II

in which

X has the meaning indicated,
30

and L is Cl, Br, OH, SCH₃ or a reactive esterified OH group,

is reacted with a compound of the formula III
35



in which

5 R^1 and R^2 have the meanings indicated,

or

10 b) in a compound of the formula I, a radical X is converted into another radical X by hydrolysing an ester group to a COOH group or converting a COOH group into an amide or into a cyano group

or

15 c) in a compound of the formula I, a radical R^1 and/or R^2 is converted into another radical R^1 and/or R^2 by converting an alkoxy group into a hydroxyl group,

20 and/or a compound of the formula I is converted into one of its salts.

4. Process for the production of pharmaceutical preparations, characterized in that a compound of the formula I according to Claim 1 and/or one of its physiologically acceptable salts is brought into a suitable dose form together with at least one solid, liquid or semi-liquid vehicle or excipient.

30 5. Pharmaceutical preparation, characterized in that it contains at least one compound of the formula I according to Claim 1 and/or one of its physiologically acceptable salts.

35 6. Compounds of the formula I according to Claim 1 and their physiologically acceptable salts for the

control of diseases of the cardiovascular system and for the treatment and/or therapy of potency disorders.

7. Medicaments of the formula I according to Claim
5 1 and their physiologically acceptable salts as phosphodiesterase V inhibitors.


8. Use of compounds of the formula I according to
Claim 1 and/or their physiologically acceptable salts
10 for the production of a medicament.

9. Use of compounds of the formula I according to
Claim 1 and/or their physiologically acceptable salts
for the production of a medicament for the treatment
15 and/or therapy of potency disorders.

2007-03-15 15:15:15

Abstract

Thienopyrimidines of the formula I



and their physiologically acceptable salts,

in which

R¹, R² and X have the meanings indicated in Claim 1, exhibit phosphodiesterase V inhibition and can be employed for the treatment of disorders of the cardiovascular system and for the treatment and/or therapy of potency disorders.

Docket No.
Merck

Declaration and Power of Attorney For Patent Application English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

THIENOPYRIMIDINES AS PHOSPHODIESTERASE INHIBITORS

the specification of which

(check one)

- ☐ is attached hereto.
- ☒ was filed on 7 JUNE 2000 as United States Application No. or PCT International Application Number PCT/EP00/05278 and was amended on _____ (if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Not Claimed

199 28 146.7 Germany 06/19/99
(Number) (Country) (Day/Month/Year Filed)

☐

(Number) (Country) (Day/Month/Year Filed)

☐

(Number) (Country) (Day/Month/Year Filed)

☐

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

I hereby claim the benefit under 35 U.S.C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States of PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112. I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C.F.R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (list name and registration number)

L. William Millen (Reg. No. 19,544)

John L. White (Reg. No. 17,746)

Anthony J. Zelano (Reg. No. 27,969)

Alan E.J. Branigan (Reg. No. 20,565)

John R. Moses (Reg. No. 24,983)

Harry B. Shubin (Reg. No. 32,004)

Brion P. Heaney (Reg. No. 32,542)

Richard J. Traverso (Reg. No. 30,595)

Diana Hamlet-King (Reg. No. 33,302)

John A. Sopp (Reg. No. 33,103)

Richard E. Kurtz (Reg. No. 33,936)

Richard M. Lebovitz (Reg. No. 37,067)

John H. Thomas (Reg. No. 33,460)

Send Correspondence to: MILLEN, WHITE, ZELANO & BRANIGAN, P.C.

Arlington Courthouse Plaza I

2200 Clarendon Blvd., Suite 1400

Arlington, VA 22201

Direct Telephone Calls to: (name and telephone number)

John A. Sopp - (703) 812-5315

Dr. Rochus

Full name of sole or first inventor	<u>100 JONAS, Rochus</u> <i>Rochus Jonas</i>	30.04.2002
Sole or first inventor's		Date
Residence	<u>Stormstrasse 7, D-64291 Darmstadt, Germany</u> <i>DEX</i>	
Citizenship	<u>Germany</u>	
Post Office Address	<u>c/o Merck KGaA, Frankfurter Str. 250, 64291 Darmstadt/Germany</u>	

Full name of second inventor, if any	<u>200 SCHELLING, Pierre</u>	30.04.2002
Second inventor's signature	<i>Pierre Schelling</i>	Date
Residence	<u>Bordenbergweg 17, D-64291 Darmstadt Muehlthal, Germany</u> <i>DEX</i>	
Citizenship	<u>Germany</u>	
Post Office Address	<u>c/o Merck KGaA, Frankfurter Str. 250, 64293 Darmstadt, Germany</u>	

Full name of third inventor, if any 300 KLUXEN, Franz-Werner		30.04.2002
Third inventor's signature <i>Franz-Werner Kluxen</i>		Date
Residence Bessunger Strasse 3, D-64285 Darmstadt, Germany DEX		
Citizenship Germany		
Post Office Address c/o. Merck KGaA, Frankfurter Str. 250, 64291 Darmstadt, Germany		

Full name of fourth inventor, if any 400 CHRISTADLER, Maria		30.04.2002
Fourth inventor's signature <i>Maria Christadler</i>		Date
Residence Duerer Strasse 10, D-63322 Roedermark, Germany DEX		
Citizenship Germany		
Post Office Address c/o Merck KGaA, Frankfurter Str. 250, 64291 Darmstadt, Germany		

Full name of fifth inventor, if any	
Fifth inventor's signature	Date
Residence	
Citizenship	
Post Office Address	

Full name of sixth inventor, if any	
Sixth inventor's signature	Date
Residence	
Citizenship	
Post Office Address	